Veeva Vault CTMS Gains Momentum as Industry Moves to Unify Clinical Applications and Processes

Modern CTMS cloud application streamlines trial management and
delivers end-to-end visibility of clinical trials on one platform

CHICAGO–(BUSINESS WIRE)–DIA 2017 Annual Meeting — Today at the Drug Information
Association’s annual meeting (DIA), Veeva
(NYSE: VEEV) announced that Veeva
Vault CTMS
is gaining momentum as customers drive toward a unified
clinical operating model. Within just two months of the product’s
release, five customers, including a top 50 global pharmaceutical
company, are implementing Veeva Vault CTMS. Veeva Vault CTMS is the
industry’s first application that unifies global data, content, and
processes across clinical operations on a single cloud platform.

Life sciences companies are experiencing widespread challenges with
legacy CTMS applications, according to the Veeva
2017 Unified Clinical Operations Survey
, one of the industry’s
largest surveys of clinical operations professionals. Nearly all
sponsors say their CTMS applications are limiting their organization’s
ability to improve clinical operations.1 This is prompting
companies to unify their processes and provide one source of data and
information across their operations.

“Veeva Vault CTMS establishes a new era of innovation in clinical trial
management with an easy-to-use, intuitive design,” said Lynn Sutton,
vice president, Clinical Operations, at inSeption Group, a new Veeva
Vault CTMS customer. “Veeva has a track record of helping their
customers be successful. We expect to drive new levels of efficiency and
productivity by streamlining our clinical processes.”

There is an industrywide drive toward a unified clinical operating
model. Organizations cite the need to unify applications across their
clinical operations for faster study execution and improved study
quality. However, the majority of companies have challenges integrating
CTMS with other clinical applications, which is limiting their ability
to improve operations. 2

“The ability to bring together CTMS, eTMF, and study start-up on a
single, modern cloud platform is a real game-changer,” said Edward
Leftin, manager, Clinical Information Systems, at Ora Inc., another
recent Veeva Vault CTMS customer. “Veeva will enhance our ability to
leverage the same business processes and workflows throughout the
lifecycle of all our studies.”

Veeva Vault CTMS is part of the Veeva
Vault Clinical Suite
, the industry’s only cloud platform that
combines EDC, eSource, CTMS, eTMF, study-startup, and site document
exchange across clinical data management and clinical operations.
Veeva’s suite of applications empowers teams with global visibility of
trial processes and information in one unified system. Now organizations
can easily manage their end-to-end trial portfolio and make better,
informed decisions.

“The industry has been held back by process and system silos for
decades,” said Jennifer Goldsmith, senior vice president of Veeva Vault.
“Customer response to the Veeva Vault Clinical Suite has been
overwhelmingly positive because, for the first time, they can unify
their processes to improve study execution and quality, and gain insight
across the clinical lifecycle.”

In related news today, preliminary findings from the Veeva 2017
Unified Clinical Operations Survey
are now available. The survey
examines the life sciences industry’s progress toward a unified clinical
environment by gathering the experiences and opinions of 300 clinical
operations professionals from around the globe. Read today’s press
or download the full survey

To learn more about Veeva Vault CTMS, watch the online
or read the whitepaper, How
to Stop Worrying and Love Your CTMS

Additional Information

For more on Veeva Vault CTMS, visit:

For more on Veeva Vault Clinical Suite, visit:

Connect with Veeva on LinkedIn:

Follow @veevasystems on Twitter:

Like Veeva on Facebook:

About Veeva Systems

Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva has more than 525 customers, ranging from the
world’s largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices in Europe,
Asia, and Latin America. For more information, visit

Forward-looking Statements

This release contains forward-looking statements, including the market
demand for and acceptance of Veeva’s products and services, the results
from use of Veeva’s products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-Q for the period ended April 30, 2017. This is available on the
company’s website at
under the Investors section and on the SEC’s website at
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to

1Veeva 2017 Unified Clinical Operations Survey (Veeva
Systems), June 19, 2017

2Veeva 2017 Unified Clinical Operations Survey (Veeva
Systems), June 19, 2017


Veeva Systems
Roger Villareal, 925-264-8885
Barbadora, 610-420-3413